CareDx Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

CDNA$84.42+7.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data)

	Year Ended December 31,
	2023	2022	2021
Revenue:
Testing services revenue	$209,685	$263,748	$259,285
Product revenue	33,517	29,251	26,832
Patient and digital solutions	37,122	28,794	10,280
Total revenue	280,324	321,793	296,397
Operating expenses:
Cost of testing services	57,642	72,286	71,251
Cost of product	18,379	17,639	18,930
Cost of patient and digital solutions	25,978	22,287	7,208
Research and development	81,866	90,388	76,525
Sales and marketing	83,334	96,027	77,245
General and administrative	117,868	100,397	74,964
Restructuring costs	2,320	—	—
Litigation expense (Note 17)	96,300	—	—
Total operating expenses	483,687	399,024	326,123
Loss from operations	(203,363)	(77,231)	(29,726)
Other income (expense):
Interest income, net	11,867	3,762	160
Change in estimated fair value of common stock warrant liability	10	107	106
Other income (expense), net	1,343	(2,872)	(2,628)
Total other income (expense)	13,220	997	(2,362)
Loss before income taxes	(190,143)	(76,234)	(32,088)
Income tax (expense) benefit	(141)	(379)	1,426
Net loss	$(190,284)	$(76,613)	$(30,662)
Net loss per share (Note 3):
Basic	$(3.54)	$(1.44)	$(0.59)
Diluted	$(3.54)	$(1.44)	$(0.59)
Weighted-average shares used to compute net loss per share:
Basic	53,764,705	53,321,625	52,241,076
Diluted	53,764,705	53,321,625	52,241,076

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.